Kornimate/medical-research-clean huggingface dataset:
effects of playstation®vr on the hrqol in stroke patients undergoing inpatient rehabilitation

Conditions: Stroke

Summary: compared to conventional rehabilitation therapy, the full-immersive commercial game (cg) system, in the form of available video game, could safely provide more positive effect on health-related quality of life (hrqol) and motor function in post-stroke patients. the study aims to perform the research from 2019/7/1 to 2021/6/30 and enrolls a total of 80 participants. stroke participants are recruited from the rehabilitation ward of cgmh hospital. the inclusion criteria are (a) first-time unilateral cerebral stroke, (b) stroke onset less or equal to 1 year, (c) admission to the rehabilitation ward, (d) ages 20-80 years, (e) spasticity of paretic arm ≤ grade 2 in the modified ashworth scale, and (f) no active medical problems such as fever, pneumonia, or scabies. the exclusion criteria are (a) brainstem or cerebellar stroke, (b) epilepsy history, including photosensitive epilepsy, (c) previous or active heart diseases, such as myocardial infarction or angina, (d) visuospatial problems related to stroke, such as hemianopia or hemineglect, (e) paretic upper limb reaches brunnstrom recovery stage vi, (f) severe aphasia, (g) severe cognitive impairment, and (h) poor cooperation with assessments. all participants are randomly allocated to study group and control group. participants in the control group receive conventional rehabilitation therapy over 50 minutes on weekdays. participants in the study group receive conventional rehabilitation therapy over 50 minutes on weekdays and 7 sessions (flexible schedule in different day) of playstation®vr of 20 minutes each in the main 16-day study period. pre-intervention, post-intervention, and 3-month follow-up hrqol will be assessed by the stroke impact scale 3.0. motricity index and fugl-meyer assessment, functional independence measure, and arm movement ratio will also be checked before intervention, after intervention, and at 3-month follow-up. the safety outcome, intervention-related adverse events or any serious adverse events, during study period will be recorded.


Eligibility criteria:
inclusion criteria: * first-time unilateral cerebral stroke * stroke onset less or equal to 1 year * admission to the rehabilitation ward * ages 20-80 years * spasticity of paretic arm ≤ grade 2 in the modified ashworth scale * no active medical problems such as fever, pneumonia, or scabies exclusion criteria: * brainstem or cerebellar stroke * epilepsy history, including photosensitive epilepsy * previous or active heart diseases, such as myocardial infarction or angina * visuospatial problems related to stroke, such as hemianopia or hemineglect * paretic upper limb reaches brunnstrom recovery stage vi * severe aphasia * severe cognitive impairment * poor cooperation with assessments

Keywords: stroke virtual reality rehabilitation
tap-patients with robotic assisted lap prostatectomy

Conditions: Postsurgical Pain; Analgesia; Prostatectomy

Summary: the purpose of the study is to assess the safety and efficacy of exparel when administered via infiltration into the transversus abdominis plane (tap) to prolonged postsurgical analgesia in men undergoing robot-assisted laparoscopic prostatectomy.

assess the safety and efficacy of exparel when administered via infiltration into the transversus abdominis plane (tap) to provide prolonged postsurgical analgesia in men undergoing robot-assisted laparoscopic prostatectomy. the primary endpoint is the duration of abdominal analgesia from the infiltration into the tap as measured by the time to the subject's first postsurgical opioid administration.

Eligibility criteria:
inclusion criteria: * male subjects, aged 18-75. * american society of anesthesiology (asa) physical status 1-3. * undergoing robot-assisted laparoscopic prostatectomy performed by a single surgeon (ingolf tuerk, md). * subjects must be physically and mentally able to participate in the study and complete all study assessments. * subjects must be able to give fully informed consent to participate in this study after demonstrating a good understanding of the risks and benefits of the tap infiltration. exclusion criteria: * demonstrated hypersensitivity or idiosyncratic reactions to amide-type local anesthetics. * inability to tolerate oxycodone with acetaminophen (e.g. percocet). * any subject whose anatomy or surgical procedure in the opinion of the investigator might preclude the potential successful performance of a tap. * any subject who in the opinion of the investigator might be harmed or be a poor candidate for participation in the study. * subjects who have received any investigational drug within 30 days prior to study drug administration or planned administration of another investigational product or procedure during their participation in this study.

Keywords: tap, robot-assisted prostatectomy
ultrasound guided adductor canal block versus femoral nerve block for quadriceps strength and fall-risk

Conditions: Quadriceps Muscle Weakness; Adductor Muscle Weakness; Fall Risk

Summary: our objective was to determine if an ultrasound guided acb can preserve quadriceps strength, thus minimizing weakness of knee extension compared with ultrasound guided femoral nerve block. our primary outcome was the percent of maximum voluntary isometric contraction (mvic) of knee extension preserved at 30 mins after either an acb or fnb. secondary outcomes included mvic of knee extension at 60 min, hip adduction at 30 and 60 mins, and assessment of fall risk with the berg balance scale (bbs) at 30 minutes.


Eligibility criteria:
inclusion criteria: * adults (\>18yrs) * asa 1-2 exclusion criteria: * bmi \>30 * allergy to local anesthetics * pre-existing gait disturbance * pre-existing neuropathy
automated diagnostic performance of smartwatch ecg for arrhythmia detection using the pulseai neural network.

Conditions: Arrhythmias, Cardiac

Summary: the study is to evaluate the performance of the pulseai neural network technology at interpreting ecg data recorded using a single-lead smartwatch (apple watch).

under subject consent, subjects will have a 12-lead ecg immediately followed by a smartwatch ecg. the heart rhythm and ecg interval measurements will be compared between the 12-lead ecg and smartwatch ecg. the arrhythmias will include: * atrial fibrillation/flutter * tachycardia * bradycardia * premature atrial contractions * premature ventricular contractions

Eligibility criteria:
inclusion criteria: * patient aged 22 or older, able and willing to participate in the study * patient admitted to hospital for ablation, cardioversion, or cardiac electrophysiological exploration. * patient who has read the information note and has given their consent before any procedure related to the study. exclusion criteria: * patient with a pacemaker, implantable defibrillator or cardiac resynchronisation therapy device.
oocyte retrieval progesterone levels and ivf

Conditions: Hormone Disturbance

Summary: objective: to assess whether basal hormonal level can predict the elevation of p4 on the day of oocyte retrieval, as well as to examine the impact of p4 elevation on the day of oocyte retrieval on the outcome of assisted reproduction. design: prospective cohort study setting: department of in vitro fertilization, gynecology and obstetrics institute, clinical center of serbia patient(s): one hundred sixty four patients enrolled in the art procedure main outcome measure(s): pregnancies, miscarriages, biochemical pregnancies and deliveries

a prospective clinical trial was conducted at the clinic for gynecology and obstetrics clinical center of serbia from january 1st to december 31st 2015. the study included 164 patients enrolled in the art procedure at the clinic. basal hormonal status - serum levels of estradiol (e2 - pg/ml), progesterone (p4 - ng/ml), follicle-stimulating hormone (fsh - miu/ml), luteinizing hormone (lh - miu/ml) and anti-mullerian hormone (amh - ng/l) were measured on the 2ndor 3rd cycle day before stimulation commencement. during cos levels of estradiol were determined, while levels of progesterone were determined on the day of oocyte retrieval i.e. aspiration. blood samples were taken by vacutainer tubes (bd vacutainer systems) and centrifuged according to the manufacturer's instructions for the preparation of the serum samples. amh value (gen ii elisa ref. no. a79765; beckman coulter) in serum was measured by elisa (enzyme-linked immunosorbent assay), 1 ng / ml). fsh, lh, estradiol, and progesterone were analyzed by chemiluminescent immunoassay (access 2 immunoassay system, beckman coulter). the main outcome measures were the procedure success as well as the pregnancy outcome. pregnancy was confirmed by a positive finding of serum β-hcg (\>25 miu/ml) 14 days after embryo transfer. clinical pregnancies were confirmed by transvaginal ultrasound findings of a gestational sac with a vital embryo at the 6th gestational week.

Eligibility criteria:
inclusion criteria: * 18 to 40 years of age * bmi of 18 to 30 kg/m2 * regular menstrual cycles from 25 to 32 days * established diagnosis of infertility. exclusion criteria: * less then 18 or more then 40 years old * bmi less then 18 or more then 30 kg/m2 * irregular menstrual cycles
choroidal and retinal thickness following strabismus surgery

Conditions: Strabismus; Retinal Thickening

Summary: prospective study, conducted at tanta university ophthalmology department measurement of macular and choroidal thickness before and after strabismus surgery

this is a prospective study and will be conducted in tanta university hospital * duration: february 2020 till may 2020 and may be extended * the study will include 30 patients who suffer from esotropia or exotropia, inferior oblique (io) over-action with or without any other type of horizontal deviation pre-operative measurement of the macular and choroidal thickness by enhanced depth imaging optical coherence tomography (edi-oct). post-operative measurement: first day, first week, one month then 3 months.

Eligibility criteria:
inclusion criteria: * no prior history of ocular surgery or trauma * normal ocular examination findings * no medical or family history of retinal disease, glaucoma or diabetes mellitus. exclusion criteria: * patients with orbital and/or craniofacial abnormalities * patients with sensory or restrictive strabismus or neurological disease * preoperative retinal or macular pathology * patient who is unable to cooperate to do oct scanning
diabetes complications and the risk of cardiovascular and cerebrovascular diseases

Conditions: Diabetes Complications; Cardiovascular Diseases; Cerebrovascular Disease

Summary: this study is intended to include 3000 diabetic patients in our hospital to collect complete medical history data, comprehensively improve the screening of diabetic complications and cardiovascular and cerebrovascular risk assessment.

with the economic development and lifestyle change, the incidence and prevalence of diabetes are increasing year by year in both china and the world. diabetics are associated with a significantly increased risk of cardiovascular and cerebrovascular disease. it is a cross-sectional study. this study intended to include about 3000 adult patients with previously diagnosed diabetes mellitus, then collect their anthropometric data (age, gender, weight, height, waist circumference, hip circumference and etc.), life history (diet, exercise, smoking, drinking and etc.), medical history, familial medical history, clinical testing results about their diabetes complication, and make a comprehensive assessment of their cardiovascular and cerebrovascular risks. these data will be used to make further research about the diabetes complication and cardiovascular and cerebrovascular disease.

Eligibility criteria:
inclusion criteria: * diabetic symptoms with: plasma glucose level at any time ≥11.1mmol/ l (200mg/ dl), or fasting plasma glucose level ≥7.0mmol/ l (126mg/ dl), or plasma glucose level ≥11.1mmol/ l (200ng/ dl) for 2 h in ogtt test, or hba1c ≥6.5%; or those without typical symptoms should repeated the tests in another day. * han chinese. * willingness to participate. exclusion criteria: * secondary diabetes. * participants in other clinical trials.
pediatric intubation during cpr

Conditions: Cardiac Arrest

Summary: we hypothesized that the video-laryngoscopes are beneficial for intubation of pediatric manikins while performing cpr. in the current study, we compared effectiveness of two video-laryngoscopes (the coopdech video laryngoscope portable vlp-100 and the flexible videoendoscope: atmos scope) and optical-laryngoscope (the airtraq) during resuscitation with uninterrupted chest compressions using an child manikin.


Eligibility criteria:
inclusion criteria: * give voluntary consent to participate in the study * minimum 1 year of work experience in emergency medicine * experienced emergency medical personnel (physicians, nurses, paramedics) exclusion criteria: * not meet the above criteria * wrist or low back diseases

Keywords: intubation child resuscitation simulation endotracheal
a study of fixed dose versus serum level-based titration regimen of vitamin d supplementation in dialysis patients

Conditions: Vitamin D Deficiency; End Stage Renal Disease

Summary: vitamin d insufficiency, defined as serum 25-hydroxyvitamin (oh) d level less than 30 ng/ml, is highly prevalent not only in the general population but also in chronic kidney disease (ckd) population. many guidelines including the national kidney foundation-kidney disease outcomes quality initiative (nkf-kdoqi) have consistently recommended vitamin d supplementation in patients with pre-dialysis ckd with vitamin d insufficiency with ergocalciferol or cholecalciferol to achieve 25(oh)d level of more than 30 ng/ml using serum levels-based titration regimen. however, this protocol has not been studied in end stage kidney disease patients treated with maintenance dialysis.

the investigators plan to conduct a randomized study comparing the two different protocols between serum 25(oh)d level-based titration regimen and fixed dose of ergocalciferol supplementation among dialysis patients for a total period of 6 months. at the study completion, investigators also plan to compare the proportion of participants achieving serum 25(oh)d of more than 30 ng/ml, ckd-related metabolic and bone parameters as well as non-skeletal effect of vitamin d supplementation for each group.

Eligibility criteria:
inclusion criteria: * age \> 18 years * on maintenance dialysis (hemodialysis or peritoneal dialysis) \> 3 months * 25(oh)d \< 30 ng/ml * able to provide inform consent form exclusion criteria: * current ergocalciferol or cholecalciferol treatment * known allergy to ergocalciferol * active inflammation or infection * advanced stage of cancer * pregnancy * lactation * on immunosuppressive drugs or corticosteroids

Keywords: vitamin d insufficiency dialysis ergocalciferol
vaginal cleansing at cesarean delivery to reduce infection: a randomized, controlled trial

Conditions: Cesarean Section; Endometritis; Surgical Wound Infection

Summary: the objective of the project is to find out whether cleansing the vagina before a cesarean delivery decreases the risk of complications and infections after having the baby. if this is the case, cleansing the vagina before cesarean delivery can help improve outcomes for many women and make their early postpartum recovery much more pleasant, giving a healthier start for the family.

infectious morbidity frequently complicates cesarean delivery. endometritis can complicate the postoperative course of a cesarean delivery 6-27% of the time. this complication, up to 10 times more frequent than after vaginal delivery, can lead to serious complications. additionally, cesarean deliveries are frequently complicated by maternal fever and wound complications including seroma, hematoma, infection, and separation. these morbidities can lead to significant delay in a return to normal function. our study will randomize 1000 women who are about to undergo a cesarean delivery into one of two groups. the control group will receive the standard surgical preparation of the abdomen alone, the current standard pre-cesarean preparation. the other group will also receive a povidone iodine washing/scrub of the vagina before the cesarean delivery. maternal and surgical variables will be recorded. at one months postpartum, maternal outpatient data will be reviewed and the incidence of postpartum uterine infection, wound separations, and other wound and infectious complications will be determined and compared between the two treatment groups. comparison: women receiving standard surgical abdominal cleansing versus women receiving standard abdominal and preoperative vaginal cleansing before cesarean delivery.

Eligibility criteria:
inclusion criteria: * woman undergoing cesarean delivery * at least 18 years of age exclusion criteria: * allergy to iodine containing solutions * planned cesarean hysterectomy * prisoner

Keywords: povidone iodine postoperative infection presurgical cleansing
effect of zt-01 on glucagon during hypoglycemia in type 1 diabetes mellitus

Conditions: Type 1 Diabetes; Hypoglycemia

Summary: the purpose of this study is to determine whether zt-01 increases the glucagon response to hypoglycemia in type 1 diabetes (t1d). zt-01 is a specific somatostatin (sst) type 2 receptor antagonist hypothesized to increase the counterregulatory glucagon release during hypoglycemia, which is impaired in diabetes, and may thus reduce the occurrence of hypoglycemia. approximately 25 participants with well-controlled type 1 diabetes will be recruited to a crossover study and be randomized to the order in which they receive a single administration of placebo, low dose and high dose zt-01 during three euglycemic-hypoglycemic clamps 2 to 6 weeks apart, with a follow-up visit approximately 1 week after the final clamp. participants will stay overnight in the clinic before each clamp, and their plasma glucose (pg) will be kept at euglycemic levels with iv insulin and dextrose as needed. the following morning, the clamp will begin and the subject's pg will be kept at 5.5 mmol/l (euglycemia) with variable iv insulin (and dextrose as needed). study treatment will be administered during this euglycemic period, and then insulin will be increased so that pg falls to a plateau of mild hypoglycemia, and then increased further to clinically significant hypoglycemia. release of glucagon and other counterregulatory hormones will be measured, and a symptom score will be completed, during euglycemia before and following study treatment, and during each level of hypoglycemia. following the clamp, the participant's blood glucose will be returned to normal levels prior to leaving the clinic.


Eligibility criteria:
inclusion criteria: * type 1 diabetes for at least 5 years and receiving insulin as the only t1d therapy * hba1c ≥6.0 and ≤9.0 % * bmi ≥18 to ≤27 kg/m\^2 * normal thyroid function exclusion criteria: * impaired hypoglycemia awareness * severe hypoglycemia or diabetic ketoacidosis (dka) within 3 months * abnormal blood pressure or ecg, clinically significant cardiovascular, cerebrovascular or peripheral vascular disease * history of pheochromocytoma, insulinoma, glucagonoma, acromegaly, cushing's disease, glycogen storage disease or adrenal insufficiency; ongoing or previous treatment with octreotide, lanreotide or pasireotide * current use of systemic corticosteroids or beta-blockers

Keywords: hypoglycemic clamp glucagon counterregulation
bacterial genomic sequencing in overactive bladder

Conditions: Overactive Bladder

Summary: no one really knows what causes overactive bladder syndrome (oab). urinary tract infection (uti)causes similar symptoms to oab with the difference being the presence of bacteria, as evidenced by routine microbiology cultures. recent work by the group on the genitourinary microbiome (gum) has shown that female urine, even in the absence of culture evidence of bacteria does have evidence of bacterial dna. bacterial 16s rrna can be isolated from urine and sequenced to identify bacterial species present in urine. from this the investigators can hypothesize that urinary bacteria contribute to urinary symptoms and that there is a difference in the bacterial communities in the urine of women who respond to solifenacin, a drug used to treat oab, versus those that do not.

this is a prospective study with two groups: women who have accepted a clinical recommendation for oab treatment with solifenacin and a comparator (control) group of women unaffected by oab. all women will have a baseline urine assessment with bacterial genome sequencing. solifenacin treated patients will also have urine assessments with bacterial genomic sequencing at 4 and 12 weeks on treatment.

Eligibility criteria:
inclusion criteria: controls: women without bother from urinary symptoms will be screened for potential study participation using the pelvic floor distress inventory (pfdi). women with negative urinary responses will be further screened for participation using the following eligibility criteria: * no anticholinergic medications for bladder conditions, * no antibiotic exposure in the past 4 weeks for any reason, * no immunologic deficiency, * no pelvic malignancy or pelvic radiation, and * untreated symptomatic pop \> pop-q stage ii. oab cohort: women with bother from overactive bladder symptoms will be screened for potential study participation using the pelvic floor distress inventory (pfdi). women with positive urinary responses for urge predominant symptoms will be further screened for participation using the following eligibility criteria: * willing to take solifenacin as treatment for oab, * no neurological disease known to affect the lower urinary tract, * no current uti (based on urine dipstick) or recurrent uti, * no antibiotic exposure in the past 4 weeks for any reason, * no immunologic deficiency, * no pelvic malignancy or pelvic radiation, * untreated symptomatic pop \> pop-q stage ii, * no contraindications to receiving solifenacin. exclusion criteria: * women who are of child-bearing potential who are pregnant, nursing, intending to become pregnant during the study or not practicing a reliable form of contraception are also excluded.

Keywords: overactive bladder oab urinary tract infection uti microbiome bacteria solifenacin 16s rrna sequence